Tam Duc Cardiology hospital Joint Stock Co
UUPCOM:TTD73,000.00
VND
-14,900.00
(-16.95%)
ISIN
VN000000TTD8
Return %
Stock
S&P 500
1Y
86.94
14.20
3Y
82.73
81.12
5Y
174.44
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- Sector
- Health services
- Industry
- Hospital/Nursing management
- Address
- Ho Chi Minh City Vietnam
- IPO Date
- Feb 6, 2017
- Website
- tamduchearthospital.com
- Similar Companies
- Business
- Tam Duc Cardiology Hospital Joint Stock Company (UPCoM: TTD) is a Vietnam-based healthcare provider specializing in high-tech cardiovascular diagnostic, interventional, surgical, and emergency medical services. Founded under national healthcare socialization initiatives and commencing clinical operations in March 2006, the company is headquartered in Ho Chi Minh City, Vietnam, where it operates a specialized cardiovascular facility with an inpatient capacity of approximately 250 beds. The company provides a comprehensive range of clinical and surgical cardiovascular healthcare services categorized into specialized medical divisions: Interventional Cardiology, providing coronary angiography, percutaneous coronary intervention (PCI), coronary stent placement, balloon angioplasty, transcatheter aortic valve implantation (TAVI), and structural heart occlusion procedures; Cardiac and Vascular Surgery, offering open-heart surgery, coronary artery bypass grafting (CABG), heart valve repair and replacement using Carpentier techniques and sutureless valves, minimally invasive cardiac surgery (MICS), congenital heart defect corrections, peripheral vascular procedures, and intracardiac tumor resections; Electrophysiology and Pacing, delivering electro-anatomical mapping, radiofrequency catheter ablation for complex cardiac arrhythmias, and the implantation of permanent pacemakers, implantable cardioverter-defibrillators (ICD), and cardiac resynchronization therapy (CRT) systems; Pediatric Cardiology, offering diagnostic screening, neonatal critical care, and corrective interventions for congenital cardiovascular conditions; Intensive Care and Emergency Medicine, operating 24/7 emergency resuscitation, coronary care units (CCU), intensive care units (ICU), and hybrid operating suites; and Diagnostic and Outpatient Services, including 2D/3D transthoracic and transesophageal echocardiography, Holter monitoring, exercise stress testing, multi-slice computed tomography (MSCT) angiography, routine cardiovascular screenings, clinical laboratory testing, and inpatient pharmaceutical dispensing. In recent corporate and operational developments, the company strengthened its balance sheet in 2026 by executing a 100% bonus share issuance, doubling its charter capital from VND 155.5 billion to VND 311 billion to support ongoing operational scaling and medical equipment upgrades. The company has maintained a strong capital return profile, executing consistent 33% annual cash dividend distributions throughout recent fiscal periods from 2023 to 2025. Operationally, the hospital continues to advance its clinical capabilities by scaling minimally invasive cardiac surgery (MICS) procedures, modernizing hybrid operating theater infrastructure, upgrading electrophysiology mapping systems, and sustaining strategic medical collaborations alongside its long-running Charitable Heart Surgery (MT3) healthcare access initiatives.